Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
====================================================================================================================================================================================================================

* Charles M Rudin
* Hardev S Pandha
* Matthew Zibelman
* Wallace L Akerley
* Kevin J Harrington
* Daphne Day
* Andrew G Hill
* Steven J O'Day
* Timothy D Clay
* Gavin M Wright
* Ross R Jennens
* David E Gerber
* Jonathan E Rosenberg
* Christy Ralph
* David C Campbell
* Brendan D Curti
* Jaime R Merchan
* Yixin Ren
* Emmett V Schmidt
* Lisa Guttman
* Sumati Gupta